GRTX · Galera Therapeutics, Inc.

The combined 2025 and 2026 Annual Meeting of Stockholders held on May 8, 2026, resulted in stockholder approval of all seven proposals. The election of directors included J. Mel Sorensen as a Class III director and Nancy Chang and Michael Friedman as Class I directors, each to serve until the respective annual meetings in 2028 and 2029. The ratification of KPMG LLP as the independent auditor for fiscal year 2026 was approved with overwhelming support. The say-on-pay proposal and the advisory vote on frequency of future say-on-pay votes both passed, with stockholders favoring a one-year frequency, which the Board had previously recommended. The three charter amendments were also approved: increasing authorized common stock from 200 million to 400 million shares, permitting stockholder action by written consent, and authorizing a reverse stock split at a ratio between 1:75 and 1:200, if and when determined by the Board. These amendments provide the Board with additional flexibility for capital management and corporate governance. The high approval rates across all proposals indicate strong stockholder alignment with management's recommendations.